The increasing number of multidrug-resistant bacteria and the fact of antibiotic resistance is leading to a continuous need for discovering alternative treatments against infections, e.g. in the case of respiratory tract diseases. Essential oils (EOs), because of their volatility, can easily reach both the upper and lower parts of the respiratory tract via inhalation. Therefore, the aim of the present study was the antibacterial evaluation of clove, cinnamon bark, eucalyptus, thyme, scots pine, peppermint, and citronella EOs against respiratory tract pathogens such as Streptococcus pneumoniae, S. mutans, S. pyogenes, Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis. Furthermore, we wanted to compare the antibacterial effect of these EOs in two different test systems to provide data for the development of an appropriate product formulation. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined with in vitro vapor phase test (VPT) and broth macrodilution test (BDT). The chemical and percentage compositions of the EOs were determined by GC-MS and GC-FID analysis. Among the EOs, thyme was the most effective against S. mutans (MIC: 0.04 mg/mL in BDT, but cinnamon bark and clove oils also presented high inhibition in liquid medium with MIC values of 0.06 mg/mL and 0.1 mg/mL against S. pneumoniae and S. pyogenes, respectively. M. catarrhalis was the most sensitive to thyme EO (MIC: 0.09 mg/mL). Cinnamon bark EO was the most effective against Haemophilus spp. (MIC: 0.06 mg/mL). In the VPT, cinnamon bark was the most effective oil against all investigated pathogens with MIC values in the range of 15.62–90 μl/L. Surprisingly, the eucalyptus and scots pine showed weak activity against the test bacteria in both test systems. The EO of thyme, clove and cinnamon bark may provide promising antibacterial activity against respiratory tract pathogens either in liquid medium or in vapor phase. However, their effect is lower than that of the reference antibiotics. The combination of EOs and antibiotics may be beneficial in the alternative treatment of respiratory tract diseases. In vivo studies are necessary to calculate the effective dose of EOs in patients and determine their possible side effects and toxicity.

The extreme lipophilicity of essential oils (EOs) impedes the measurement of their biological actions in an aqueous environment. We formulated oil in water type Pickering Artemisia annua EO nanoemulsions (AEP) with surface-modified Stöber silica nanoparticles (20 nm) as the stabilizing agent. The antimicrobial activity of AEP and its effects on mature Candida biofilms were compared with those of Tween 80 stabilized emulsion (AET) and ethanolic solution (AEE) of the Artemisia EO. The antimicrobial activity was evaluated by using the minimum inhibitory concentrations (MIC₉₀) and minimum effective concentrations (MEC₁₀) of the compounds. On planktonic bacterial and fungal cells beside growth inhibition, colony formation (CFU/mL), metabolic activity, viability, intracellular ATP/total protein (ATP/TP), along with reactive oxygen species (ROS) were also studied. Artemisia annua EO nanoemulsion (AEP) showed significantly higher antimicrobial activity than AET and AEE. Artemisia annua EO nanoemulsions (AEP) generated superoxide anion and peroxides-related oxidative stress, which might be the underlying mode of action of the Artemisia EO. Unilamellar liposomes, as a cellular model, were used to examine the delivery efficacy of the EO of our tested formulations. We could demonstrate higher effectiveness of AEP in the EO components’ donation compared to AET and AEE. Our data suggest the superiority of the AEP formulation against microbial infections.

Zearalenone (ZEN) is a Fusarium-derived mycotoxin, exerting xenoestrogenic effects in animals and humans. ZEN and its derivatives commonly occur in cereals and cereal-based products. During the biotransformation of ZEN, its reduced metabolites, α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL), are formed; α-ZEL is even more toxic than the parent compound ZEN. Since previous studies demonstrated that ZEN and ZELs form stable complexes with β-cyclodextrins, it is reasonable to hypothesize that cyclodextrin polymers may be suitable for mycotoxin removal from aqueous solutions. In this study, the extraction of ZEN and ZELs from water, buffers, and corn beer was investigated, employing insoluble β-cyclodextrin bead polymer (BBP) as a mycotoxin-binder. Our results demonstrate that even relatively small amounts of BBP can strongly decrease the mycotoxin content of aqueous solutions (including beer). After the first application of BBP for mycotoxin binding, BBP could be completely reactivated through the elimination of ZEN from the cyclodextrin cavities by washing with a 50 v/v% ethanol-water mixture. Therefore, our study suggests that insoluble cyclodextrin polymers may be suitable tools in the future to deplete mycotoxins from contaminated drinks.

7,8-dihydroxyflavone (DHF) is a flavone aglycone which has beneficial effects in several central nervous system diseases. Most of the pharmacokinetic properties of DHF have been characterized, while only limited information is available regarding its interactions with serum albumin and biotransformation enzymes. In this study, the interactions of DHF with albumin was examined employing fluorescence spectroscopy and ultrafiltration. Furthermore, the inhibitory effects of DHF on cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and xanthine oxidase (XO) enzymes were also tested using in vitro models. Our results demonstrate that DHF forms a stable complex with albumin (K = 4.9 × 10⁵ L/mol) and that it is able to displace both Site I and Site II ligands. Moreover, DHF proved to be a potent inhibitor of each enzyme tested, showing similar or slightly weaker effects than the positive controls used. Considering the above-listed observations, the coadministration of DHF with drugs may interfere with the drug therapy due to the development of pharmacokinetic interactions.

The prevalence of chronic venous disease (CVD) is relatively high, it affects 20-80 % of the population worldwide. CVD may affect any veins in the human body, however, the veins of the lower extremities are the most susceptible to this condition. Among therapeutic possibilities for CVD, mainly chronic venous insufficiency, some medicinal plants (Ruscus aculeatus L., Aesculus hippocastanum L., Centella asiatica (L.) Urb.) and their active compounds (ruscoside, aescin, asiaticoside) or close derivatives also have important places. This review describes shortly the updated knowledge on pathophysiology, clinical manifestations, evaluation, and diagnostics of CVD as well as treatment modalities. The primary focus of this review is on the existing knowledge about botanical medications for treating chronic venous disease (CVD). It covers the chemical makeup of these plant drugs, their pharmacological effects, results from clinical trials involving humans, and any associated safety concerns.